Hepatitis A Clinical Trial
— HAVOfficial title:
Phase 4 Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine
Verified date | October 2023 |
Source | Institute of Medical Biology, Chinese Academy of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this Phase 4 trial is to assess the safety, immunogenicity, three-year immune persistence of inactivated hepatitis A vaccine (HAV) and live attenuated HAV vaccine.
Status | Completed |
Enrollment | 35000 |
Est. completion date | June 2016 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Months to 65 Years |
Eligibility | Inclusion Criteria: - Only subjects fulfilling all of the following criteria will be eligible for the study: - People aged from 18 months to 65 years old. - The subjects or subjects' guardians are able to understand and sign the informed consent - The subjects or subjects' guardians allow to comply with the requirements of the protocol - Subjects with temperature <=37.0°C on axillary setting - The subjects have signed informed consent already Exclusion Criteria: - Subjects will not be eligible for the study if any of the following criteria is met: - Subject who has a medical history of serious disease including Tumor, autoimmune disease, progressive atherosclerosis diseases or complications of diabetes, chronic obstructive pulmonary disease (copd), kidney disease, congestive heart failure etc. - Have a history of neurological symptoms or signs - Have medical history or family history relating to allergies, seizures, epilepsy, brain and spirit etc. - Suffering from serious chronic diseases - Suffering from known or suspected of diseases including respiratory diseases, acute infection , mothers have HIV infection, cardiovascular disease, severe hypertension, skin diseases, malignant tumor - Allergic to any ingredient in research, history of allergies to any vaccination (always), especially for people allergic to high protein food like eggs and milk - Any prior known or suspected damage or abnormal immune function. As for patients who are treated with immune inhibitors or immune enhancer medicine, accept with immunoglobin, blood products and plasma extraction within 3 months - Any prior diseases including human immunodeficiency virus infection or related - Bleeding constitution or prolong bleeding time situation - Accept hepatitis A vaccination within a month - Received vaccines, other immune globulin, any research drug injections in the past 4 weeks - People who had any acute illness, needed systemic antibiotics or antiviral treatment in the past 7 days - Caught a fever with axillary temperature 38°C or higher in past 3 days - Take part in another clinical researchers - Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent - Pregnancy test result is positive |
Country | Name | City | State |
---|---|---|---|
China | Institute of Medical Biology -Chinese Academy of Medical Sciences | Kunming | Yunnan |
Lead Sponsor | Collaborator |
---|---|
Institute of Medical Biology, Chinese Academy of Medical Sciences | Jiangsu Province Centers for Disease Control and Prevention |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | changes of hepatitis A antibody concentration | 1. Changes of anti-HAV antibody geometric mean concentrations at pre-vaccination, month 1,12, 24, 36, and 1 months after the booster vaccination. | up to 43 months | |
Secondary | The frequency of all the adverse events in vaccine group and placebo group | compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group. | up to 43 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03445416 -
Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
|
N/A | |
Completed |
NCT00313950 -
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
|
Phase 4 | |
Completed |
NCT00139139 -
A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A
|
N/A | |
Completed |
NCT00197171 -
Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine
|
Phase 3 | |
Completed |
NCT00139113 -
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
|
Phase 4 | |
Completed |
NCT03312699 -
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
|
Phase 1 | |
Completed |
NCT03855176 -
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
|
Phase 4 | |
Completed |
NCT00197002 -
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
|
Phase 3 | |
Withdrawn |
NCT02605538 -
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
|
N/A | |
Completed |
NCT04638335 -
What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years
|
||
Completed |
NCT00197015 -
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
|
Phase 3 | |
Active, not recruiting |
NCT06058416 -
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
|
Phase 4 | |
Completed |
NCT01453348 -
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT02002065 -
The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children
|
N/A | |
Completed |
NCT01865968 -
Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults
|
Phase 4 | |
Terminated |
NCT00119743 -
A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
|
Phase 3 | |
Completed |
NCT01000324 -
Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
|
Phase 4 | |
Completed |
NCT00289731 -
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
|
Phase 4 | |
Completed |
NCT02300792 -
The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A
|
Phase 2 | |
Completed |
NCT02601040 -
Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
|
Phase 4 |